FREQUENCY OF 30 DAYS MORTALITY IN PATIENTS OF ST-SEGMENT ELEVATION MI WITH VARYING HEMATOCRIT LEVELS

Q ALI; NA SHAHID; MI KHAN; F QAISAR; M KHALIQ

doi:10.54112/bcsrj.v2023i1.310

Authors

Q ALI Department of Cardiology, Punjab Institute of Cardiology (PIC) Lahore, Pakistan
NA SHAHID Department of Cardiology, Punjab Institute of Cardiology (PIC) Lahore, Pakistan
MI KHAN Department of Haematology, Shahida Islam Medical & Dental College Lodhran, Pakistan
F QAISAR Department of Medicine, Bahawal Victoria Hospital Bahawalpur, Pakistan
M KHALIQ Department of Medicine, Bahawal Victoria Hospital Bahawalpur, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.310

Keywords:

30 days, , mortality, ST-segment elevation MI, varying hematocrit levels

Abstract

A descriptive study was carried out in the Emergency Department of Punjab Institute of Cardiology, Lahore, from Oct 2022-April 2023 to assess the incidence of 30 days mortality in STEMI patients with varying hematocrit levels. A total of 440 cases with ST-segment elevation MI with varying hematocrit levels (anemia and erythrocytosis) were included in the study. In our study, the average age was 44.12+10.16 years, 273 (62%) were male, and 167 (37.9%) were females; frequency of different hematocrit levels was recorded, which showed that 263 (59.7%) had anemia and 177 (40.2%) had erythrocytosis. Out of 263 cases of anemia, 26 (9.8%) and out of 177 cases of erythrocytosis, 11 (6.2%) were recorded with mortality, while the remaining 237 (90.8%) cases of anemia and 166 (94.3%) of erythrocytosis had no mortality, the p-value was calculated as 0.17 which shows the insignificant difference between the two groups. We concluded that the frequency of 30 days mortality in STEMI patients is higher in anemic patients than in erythrocytosis, but hematocrit levels could be used as a biomarker for mortality in STEMI.

Downloads

Download data is not yet available.

References

Ali, A., and Ahmad, S. (2016). Frequency of Pericardial Effusion among Patients with Acute St Segment Elevation Myocardial Infarction. PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES 10, 816-818.

Aoki, J., Lansky, A. J., Mehran, R., Moses, J., Bertrand, M. E., McLaurin, B. T., Cox, D. A., Lincoff, A. M., Ohman, E. M., and White, H. D. (2009). Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 119, 687-698.

Bellwald, S., Balasubramaniam, R., Nagler, M., Burri, M. S., Fischer, S. D., Hakim, A., Dobrocky, T., Yu, Y., Scalzo, F., and Heldner, M. R. (2018). Association of anemia and hemoglobin decrease during acute stroke treatment with infarct growth and clinical outcome. PloS one 13, e0203535.

Gardner, W., and Kassebaum, N. (2020). Global, regional, and national prevalence of anemia and its causes in 204 countries and territories, 1990–2019. Current Developments in Nutrition 4, 830-830.

Greenberg, G., Assali, A., Vaknin-Assa, H., Brosh, D., Teplitsky, I., Fuchs, S., Battler, A., Kornowski, R., and Lev, E. I. (2010). Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction. The American journal of cardiology 105, 435-440.

Guedeney, P., Sorrentino, S., Claessen, B., and Mehran, R. (2019). The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert review of cardiovascular therapy 17, 151-159.

Hayıroğlu, M. İ., Keskin, M., Uzun, A. O., Yıldırım, D. İ., Kaya, A., Çinier, G., Bozbeyoğlu, E., Yıldırımtürk, Ö., Kozan, Ö., and Pehlivanoğlu, S. (2019). Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction complicated with cardiogenic shock. Heart, Lung and Circulation 28, 237-244.

Kunnas, T., Solakivi, T., Huuskonen, K., Kalela, A., Renko, J., and Nikkari, S. T. (2009). Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up. Preventive medicine 49, 45-47.

Mudumbai, S. C., Cronkite, R., Hu, K. U., Wagner, T., Hayashi, K., Ozanne, G. M., Davies, M. F., Heidenreich, P., and Bertaccini, E. (2011). Association of admission hematocrit with 6‐month and 1‐year mortality in intensive care unit patients. Transfusion 51, 2148-2159.

Parra‐Reyna, B., Padilla‐Gutiérrez, J. R., Aceves‐Ramírez, M., García‐Garduño, T. C., Martínez‐Fernández, D. E., Jacobo‐García, J. J., Valdés‐Alvarado, E., and Valle, Y. (2022). Genetic variants, gene expression, and soluble CD36 analysis in acute coronary syndrome: Differential protein concentration between ST‐segment elevation myocardial infarction and unstable angina. Journal of Clinical Laboratory Analysis 36, e24529.

Rymer, J. A., and Rao, S. V. (2018). Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. Coronary Artery Disease 29, 161-167.

Saghazadeh, A., and Rezaei, N. (2016). Inflammation as a cause of venous thromboembolism. Critical reviews in oncology/hematology 99, 272-285.

Saito, S., Krucoff, M. W., Nakamura, S., Mehran, R., Maehara, A., Al-Khalidi, H. R., Rowland, S. M., Tasissa, G., Morrell, D., and Joseph, D. (2018). Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich’s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. European Heart Journal 39, 2460-2468.

Stepien, K., Nowak, K., Skorek, P., Baravik, V., Kozynacka, A., Nessler, J., and Zalewski, J. (2019). Baseline indicators of coronary artery disease burden in patients with non-ST-segment elevation acute coronary syndrome. Minerva cardioangiologica 67, 181-190.

Timmis, A., Townsend, N., Gale, C. P., Torbica, A., Lettino, M., Petersen, S. E., Mossialos, E. A., Maggioni, A. P., Kazakiewicz, D., and May, H. T. (2020). European Society of Cardiology: cardiovascular disease statistics 2019. European heart journal 41, 12-85.

Vischetti, M., Zito, F., Donati, M. B., and Iacoviello, L. (2002). Analysis of gene-environment interaction in coronary heart disease: fibrinogen polymorphisms as an example. Italian Heart Journal 3, 18-23.

Wall, H. K., Ritchey, M. D., Gillespie, C., Omura, J. D., Jamal, A., and George, M. G. (2018). Vital signs: prevalence of key cardiovascular disease risk factors for Million Hearts 2022—United States, 2011–2016. Morbidity and Mortality Weekly Report 67, 983.